Insider Selling: GoodRx (NASDAQ:GDRX) Major Shareholder Sells $961,509.50 in Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX) major shareholder Francisco Partners Iv, L.P. sold 274,717 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $3.50, for a total transaction of $961,509.50. Following the transaction, the insider owned 777,213 shares in the company, valued at $2,720,245.50. This represents a 26.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

• On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The stock was sold at an average price of $3.52, for a total value of $1,574,351.68.
• On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The stock was sold at an average price of $3.53, for a total value of $1,666,071.75.

GoodRx Stock Performance

Shares of NASDAQ GDRX opened at $3.45 on Monday. The stock has a fifty day moving average price of $3.13 and a two-hundred day moving average price of $2.63. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.38 and a current ratio of 1.38. The firm has a market cap of $1.18 billion, a P/E ratio of 86.27, a PEG ratio of 1.72 and a beta of 1.60. GoodRx Holdings, Inc. has a 1 year low of $1.77 and a 1 year high of $5.81.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.08 EPS for the quarter, hitting analysts’ consensus estimates of $0.08. The company had revenue of $200.41 million for the quarter, compared to the consensus estimate of $193.23 million. GoodRx had a return on equity of 7.22% and a net margin of 2.07%.The company’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.09 EPS. Research analysts forecast that GoodRx Holdings, Inc. will post 0.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Weiss Ratings upgraded shares of GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, August 7th. Barclays raised their price objective on shares of GoodRx from $3.00 to $4.00 and gave the company an “underweight” rating in a research report on Thursday. UBS Group lifted their price objective on shares of GoodRx from $2.50 to $3.75 and gave the stock a “neutral” rating in a research note on Thursday, August 13th. Citigroup boosted their target price on shares of GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Finally, Wells Fargo & Company increased their target price on shares of GoodRx from $3.50 to $5.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Four research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, GoodRx presently has a consensus rating of “Hold” and an average target price of $4.23.

Hedge Funds Weigh In On GoodRx

A number of large investors have recently made changes to their positions in GDRX. Headlands Technologies LLC purchased a new stake in shares of GoodRx in the second quarter worth approximately $30,000. Technology Crossover Management X Ltd. purchased a new position in GoodRx during the second quarter valued at approximately $4,762,000. Bank of New York Mellon Corp purchased a new position in GoodRx during the second quarter valued at approximately $540,000. Essential Partners LLC grew its position in GoodRx by 375.4% during the first quarter. Essential Partners LLC now owns 14,304 shares of the company’s stock valued at $28,000 after purchasing an additional 11,295 shares in the last quarter. Finally, Amundi acquired a new position in GoodRx in the 1st quarter valued at approximately $37,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.